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Abstract
Purpose—Documenting the impact of different types of cancer on daily functioning and well-
being is important for understanding burden relative to other chronic medical conditions. This
study examined the impact of 10 different cancers and 13 other chronic medical conditions on
health-related quality of life.
Methods—Health-related quality of life data were gathered on the Medicare Health Outcomes
Survey (MHOS) between 1998 and 2002. Cancer information was ascertained using the National
Cancer Institute’s surveillance, epidemiology, and end results program and linked to MHOS data.
Results—The average SF-6D score was 0.73 (SD = 0.14). Depressive symptoms had the largest
unique association with the SF-6D, followed by arthritis of the hip, chronic obstructive pulmonary
disease/asthma, stroke, and sciatica. In addition, the majority of cancer types were significantly
associated with the SF-6D score, with significant negative weights ranging from −0.01 to −0.02 on
the 0–1 health utility scale. Distant stage of cancer was associated with large decrements in the
SF-6D ranging from −0.04 (prostate) to −0.08 (female breast).
Conclusion—A large number of chronic conditions, including cancer, are associated uniquely
with decrements in health utility. The cumulative effects of comorbid conditions have substantial
impact on daily functioning and well-being of Medicare beneficiaries.
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Introduction
The majority of US adults (133 million) have at least one chronic medical condition [1], and
12 million Americans are living with cancer [2]. Rothrock et al. [1] documented that most
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medical conditions have a negative impact on daily functioning and well-being, or health-
related quality of life (HRQOL) measured by the Patient-Reported Out-comes Measurement
Information System® (PROMIS®). Having a single condition had a negative impact on the
PROMIS® HRQOL domain scores of about 0.1–0.4 standard deviations (SDs), depending
on the condition and the specific HRQOL domain. Having multiple conditions compared to
a single condition impacted negatively in the range of 0.2–0.7 SDs.
Smith et al. [3] found that Medicare managed care beneficiaries with cancer had
significantly worse physical health (as measured by the SF-36 v.1 physical component
summary score) than those without cancer. Beneficiaries with non-small cell lung, non-
Hodgkin lymphoma, female breast, colorectal, or bladder cancer reported worse mental
health (on SF-36 v. 1 mental component summary score) than did those without cancer.
While the SF-36’s two summary scores provide useful information about physical and
mental health, a single preference-based score is very helpful when “bottom-line”
comparisons of different therapies are needed such as in comparative effectiveness research.
Preference-based measures are designed to integrate across domains of health to provide a
summary measure anchored relative to “dead” (score of 0) and “perfect health” (score of 1).
A preference-based score is essential when a decision about overall health impact is
required.
While it is apparent from the work to date that there are significant associations of cancer
with HRQOL, the relative impact of cancer and other health conditions on HRQOL overall
is unknown. Although individual unique associations of conditions on HRQOL may seem
small, a difference of about 0.03 on a 0–1 preference-based measure may be important;
interventions that produce that level of difference are non-trivial. In addition, the cumulative
effect of multiple conditions could be substantial. Because the likelihood of chronic
conditions increases with age, it is especially important to examine the impacts of these
conditions on HRQOL among older individuals.
This study uses the SF-6D [4, 5] to estimate the unique impact of different health conditions
on HRQOL for Medicare managed care beneficiaries aged 65 years or older. We also
investigate the impact of several types of cancers including both highly prevalent (prostate,
female breast, colorectal, non-small cell lung) and less common (endometrial, bladder,
melanoma, non-Hodgkin lymphoma, and kidney) cancers. We hypothesize that individuals
with cancer will have significantly worse SF-6D scores than those without a chronic medical
condition. We also hypothesize that those with cancer will have SF-6D scores that are
comparable or worse than those with chronic medical conditions other than cancer. But the
differences may vary by cancer type. For example, a previous analysis found that lung
cancer was more strongly related to decrements in physical and mental health than other




Our sample is derived from a dataset that links surveillance, epidemiology, and end results
(SEER) cancer registry information with the Medicare Health Outcomes Survey (MHOS). A
detailed description of the SEER-MHOS data is provided by Ambs et al. [6]. Briefly, the
MHOS evaluated outcomes of care provided by health maintenance organizations to
Medicare beneficiaries. During the 1998–2003 study period, the MHOS was a yearly survey
administered to a random sample of 1,000 Medicare beneficiaries from each managed care
plan under contract with the Centers for Medicare and Medicaid Services (CMS). The SEER
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program includes population-based cancer registry sites throughout the USA that collect
standardized clinical and demographic information for persons with incident cancer [7].
The linked SEER-MHOS dataset includes four MHOS cohorts (baseline and follow-up
year): 1998 and 2000; 1999 and 2001; 2000 and 2002; and 2001 and 2003. Response rates to
the MHOS baseline surveys ranged from 63 to 72 %. The majority of the MHOSs were
completed by mail (88 %), and the rest were administered by phone (12 %). In addition, 12
% of the surveys were completed by a proxy. Across the four cohorts, we identified a total
sample of 126,366 persons, both with and without cancer, age 65 or older who had
completed at least one survey and responded to the survey questions included in the
analysis.
Participants with cancer (n = 22,740; 18 % of the sample) were identified through SEER,
and the first survey completed after their cancer diagnosis was used. We restricted this
cancer subgroup to those with a first diagnosis of one of nine prevalent cancers: (1) prostate
(n = 5,593; 4 % of the sample), (2) female breast (n = 4,311; 3 % of the sample), (3)
colorectal (n = 3,012; 2 % of the sample), (4) non-small cell lung (n = 1,792; 1 % of the
sample), (5) bladder (n = 1,299; 1 % of the sample), (6) melanoma (n = 1,135; 1 % of the
sample), (7) endometrial (n = 902; 1 % of the sample), (8) non-Hodgkin lymphoma (n =
668; 1 % of the sample), and (9) kidney cancer (n = 488; 0.4 % of the sample). The
remaining cancer diagnoses were classified as “other” (n = 3,540, 3 % of the sample).
Cancer stage data came from SEER. Individuals with more than one cancer diagnosis, or
who self-reported cancer, but were not identified in SEER, were excluded. Clauser et al. [8]
reported that 13 % of the incident cases had multiple primary cancer diagnoses. For the
103,626 people without a cancer diagnosis, we included the first survey they completed.
Respondents were asked on the MHOS whether they had ever been told by a doctor that
they had any of 12 chronic medical conditions: (1) hypertension or high blood pressure (n =
66,968; 53 % of the sample), (2) arthritis of the hip (n = 44,524; 35 % of the sample), (3)
arthritis of the hand (n = 40,402; 32 % of the sample), (4) sciatica (n = 26,878; 21 % of the
sample), (5) angina or coronary artery disease (n = 18,017; 14 % of the sample), (6)
myocardial infarction or heart attack (n = 11,982; 9 % of the sample), (7) stroke (n = 9,479;
8 % of the sample), (8) congestive heart failure (n = 7,893; 6 % of the sample), (9) other
heart disease (n = 25,455; 20 % of the sample), (10) diabetes (n = 20,089; 16 % of the
sample), (11) chronic obstructive pulmonary disease (n = 15,445; 12 % of the sample), and
(12) inflammatory bowel disease (n = 5,882; 5 % of the sample). In addition, they were
asked whether they were depressed in the last year (n = 14,815; 12 % of the sample). The
percentage of the sample who reported no conditions was 13 % (n = 15,833), 21 % (n =
26,126) reported one condition, 21 % (n = 26,653) reported two conditions, and the
remainder reported 3–14 conditions (including cancer).
Measures
The MHOS includes the SF-36 health survey, version 1 [9]. We used the SF-6D preference-
based score as the dependent variable in this study. The SF-6D is computed from a subset
(11 of the 36 questions) of the SF-36 questionnaire [5]. The SF-6D reduced the SF-36 to six
domains (physical functioning, role limitations, social function, pain, emotional well-being,
vitality), each comprised of four to six levels, and jointly defined 18,000 health states.
Scoring was derived from standard gamble assessments by a population sample from the
United Kingdom [5]. We used the revised SF-6D scoring algorithm described by Brazier,
Rowen and Hanmer [10]. The algorithm produces scores ranging from 0.30 to 1.00 for those
alive [5].
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Participants’ self-reported age, gender, race/ethnicity, marital status, education, and income
came from the MHOS.
Analysis plan
The analyses were performed using SAS 9.3 and STATA 12 software. We provide
descriptive statistics for the sample, followed by least square regression adjusted means on
the SF-6D. The SF-6D mean was slightly lower than the median (0.73 vs. 0.75), indicating
minor negative skewness (−0.37) and an approximately normal distribution of standard
errors for regression coefficients [11]. We estimated the unique associations of each chronic
condition with the SF-6D, controllingfor the other conditions, education (8th grade or less;
some high school; high school graduate; some college; 4 year college graduate; >4 year
college degree), gender, marital status (married; widowed; separated; divorced; never
married), age, race/ethnicity (Hispanic; non-Hispanic white; non-Hispanic black; Asian;
American Indian; other race; race/ethnicity missing), income (<$10,000/year; $10,000–
19,999/year; $20,000–29,999/year; $30,000–39,999/year; $40,000–49,999/year; $50,000–
79,999/year; $80,000 and above; do not know or missing income), whether a proxy
completed the survey, and mode of administration (mail vs. telephone).
We also evaluated whether there were interactions between the four most prevalent cancers
(female breast, prostate, colorectal, lung) and the 13 non-cancer chronic conditions in the
model. We examined whether stage of disease was related to SF-6D scores for the four most
prevalent cancers (female breast, prostate, colorectal, non-small cell lung). For uniformity
across conditions, we coded stage of disease into localized cancer, distant (metastatic)
cancer, and onstage. Regression parameter standard errors were adjusted for clustering at the
health plan level using the sandwich estimator of variance [12].
Recycled predictions [13], or averaging of individual marginal effects, are used to
understand the incremental effect of an independent variable on a dependent variable. We
used recycled predictions to obtain adjusted SF-6D means for each cancer and non-cancer
condition group. We created two variants of these predicted score. In the first approach, we
fixed all other independent variables other than the condition being predicted at their means.
In the second approach, we fixed the 22 other conditions at zero and the remaining
independent variables at their means. The advantage of fixing the other conditions at the
mean (first approach) is that the adjusted scores correspond to the overall sample mean on
the dependent variable. However, this approach can yield counterintuitive results. In our
data, for example, the unstandardized beta for sciatica (−0.037) is more negative than for GI
(−0.031) yet the recycled prediction based on the means for the other conditions is slightly
larger for sciatica (0.701) than GI (0.700). This occurs because sciatica is more prevalent
than GI–the mean for sciatica (0.21) is larger than that for GI (0.05). Hence, when we
predict the GI score, the larger sciatica mean drives the estimated GI score down more than
the GI mean drives down the estimated sciatica score. The second approach (fixing the other
conditions at zero) avoids these sorts of differences between the betas and the recycled
predictions but the predicted scores are higher and do not correspond to the sample mean on
the dependent variable.
Results
As shown in Table 1, the sample of 126,366 respondents had an average age of 74 years
(range 65–106). Forty-five percent were male, 79 % non-Hispanic white, 60 % married, and
27 % had less than a high school degree. The median income was less than $30,000. The
average number of reported chronic medical conditions other than cancer was 2.44 (range =
0–13). Sample characteristics for those with and without cancer were similar, but those with
cancer were more likely to be male, white, and married.
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The average SF-6D score in the entire sample was 0.73 (SD = 0.14), ranging from 0.30 to
1.00. Only 0.16 and 1 % of the sample had the lowest and highest observed scores,
respectively. SF-6D scores were consistent across the 4 MHOS cohorts, with the same mean
and SD observed for each cohort as for the entire sample.
The regression model with 43 degrees of freedom in the numerator accounted for 39 % of
the (adjusted) variance in the SF-6D (see Table 2). All except two conditions (melanoma,
endometrial cancer) had significant unique negative associations with the SF-6D score. As a
sensitivity analysis to address the concern that depressive symptoms overlap with the
dependent variable, we reran the regression model without it and found little impact on the
coefficients for the other conditions.
Adjusted mean scores (recycled predictions) using the first approach (fixing other conditions
to their mean values) rounded to two decimal places were 0.73 (melanoma), 0.72
(endometrial cancer, colorectal cancer, female breast cancer, prostate cancer, bladder cancer,
non-Hodgkin lymphoma, kidney cancer, myocardial infarction/heart attack, hypertension,
angina/coronary artery disease, other heart disease), 0.71 (other cancer, non-small cell lung
cancer, diabetes, arthritis of the hand), 0.70 (congestive heart failure, arthritis of the hip,
inflammatory bowel disease, sciatica, chronic obstructive pulmonary disease), 0.69 (stroke),
and 0.61 (depressive symptoms). Adjusted mean scores using the second approach are given
in the last column of Table 2.
Only 6 of the 52 two-way interactions between the four most prevalent cancers and the 13
non-cancer conditions were statistically significant (p < 0.05). Small negative coefficients
were found for the interactions between colorectal cancer and diabetes, and lung cancer and
chronic obstructive pulmonary disease/asthma, while small positive coefficients were found
between sciatica and lung cancer, hypertension and prostate cancer, hypertension and
colorectal cancer, and other heart disease and female breast cancer. We do not interpret
these interactions given the inconsistent directions and because they could have occurred by
chance.
There were small numbers of distant stage cancer (26 female breast, 61 prostate, 48
colorectal, and 47 lung) but distant stage of disease was significantly associated with worse
health utility scores, with distant stage of disease being worse than localized disease by
0.044 for prostate cancer, 0.046 for colorectal cancer, 0.058 for lung cancer, and 0.077 for
female breast cancer.
Discussion
The average SF-6D score in this sample (0.73) is similar to the mean of 0.77 reported for
participants 70–79 years of age in the National Health Measurement Study during 2005–
2006 [14]. The lower mean in this sample is understandable given that the majority of
respondents (88 %) completed the survey by mail, whereas telephone mode of data
collection was used for the National Health Measurement Study. Telephone administration
tends to yield more positive HRQOL scores [15]. The average SF-36 v. 1 physical
component and mental component summary scores (T-score metric with 50 mean and SD of
10 in US general population) were 42 and 52, respectively. Hence, this sample of older
individuals had substantially worse physical health (large effect size) but slightly better
mental health (small effect size) than the US adult general population. The means for the
MHOS sample are very similar to those observed for persons ages 65–74 in the US general
population where the PCS and MCS were 43 and 53, respectively [16].
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The strongest association with the SF-6D preference-based score was observed for
depressive symptoms (−0.131). This is not surprising because the depression question was
the only one that had a 1-year reference period. Other health conditions captured in the
MHOS could have occurred recently or several years ago because people were asked
whether they had ever been told by a doctor that they had the condition. Further, a strong
negative association of depression with the SF-6D was expected because the measure
includes mental health items. Thus, depressive symptoms are represented to some extent on
both sides of the equation. Dropping depressive symptoms from the model had no impact on
the interpretation of the associations for the other 20 comorbid conditions that had
significant unique associations with the SF-6D score.
The largest decrements in HRQOL for the remaining conditions were observed for arthritis
of the hip, sciatica, chronic obstructive pulmonary disease/asthma, stroke, inflammatory
bowel disease, and congestive heart failure (betas ranging from −0.029 to −0.044). In
contrast, the smallest significant associations were −0.006.
The four conditions with the strongest significant unique associations with the SF-6D in this
study (arthritis of the hip, sciatica, chronic obstructive pulmonary disease/asthma, stroke)
were found to have relatively large associations with the SF-36 physical component
summary score by Smith et al. [3]. Three of the conditions also had strong associations with
the SF-36 mental health summary score, while arthritis of the hip was not as strongly related
[3].
The majority of cancer types were significantly associated with the SF-6D score, with beta
coefficients (rounded to two decimal places) ranging from −0.01 to −0.02 on the 0–1 health
utility scale. These results are similar to what was observed in a sample of 38,678
individuals from the 2000–2002 in the medical expenditure panel survey by Sullivan et al.
[17]. Specifically, Sullivan et al. [17] reported “disabilities” of −0.02 for prostate cancer,
−0.01 for breast cancer, and −0.01 for other cancer.
Walters and Brazier [18] reviewed 7 studies and found that estimates of the minimally
important difference (MID) for the SF-6D ranged from 0.01 to 0.05 with a weighted mean of
0.03. Similarly, Khanna et al. [19] reported MID estimates of about 0.03 in a sample of
persons with systemic sclerosis. Hence, the magnitudes of the unique associations of types
of cancer with health utility score are not trivial. In comparison, the largest unique
association of chronic conditions (other than depressive symptoms) with the SF-6D in the
current study was −0.04.
While the individual impact of conditions including cancer was typically not large, the
differences could matter in group comparisons. For example, a difference of 0.02 on the
utility scale would be considered cost-effective if it cost about $1,000 to produce (i.e.,
$50,000/QALY). Moreover, the cumulative effect of multiple conditions is substantial as
evidenced by the plethora of significant unique associations in the regression model. In fact,
the adjusted score for those reporting any one condition was on average 0.03 lower than
those reporting no conditions, while the adjusted score for those reporting two or more
conditions was on average 0.11 lower (results not reported earlier). Finally, the decrements
in HRQOL cumulate over time, so the full impact relative to those without chronic
conditions is the observed decrement multiplied by the number of years with the condition.
We found that stage of disease had a profound impact on HRQOL. Those with distant
(metastatic) stage of disease had health utility scores that were 0.044–0.077 worse than those
with localized cancer. Because the number of people with distant stage of disease was so
small in the dataset, the overall relationship of cancer with health utility scores was
determined entirely by those with less advanced disease when stage was excluded from the
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model. The large negative decrement in HRQOL in late stage of disease high-lights the
importance of clinical interventions to ameliorate these negative effects on functioning and
well-being.
Although this study has a number of strengths, it also has limitations. Due to the cross-
sectional design, we are unable to make definite conclusions about directionality. In
addition, other than stage of cancer the study does not have information about the severity of
the chronic conditions examined, nor the time when the condition was diagnosed. A
previous study found similar SF-36 scores by time since diagnosis but there was some
indication of a healthy survivor effect in colorectal and lung cancer patients [3]. We also
have not captured information about some common conditions among older individuals such
as osteoporosis, benign prostatic hypertrophy, or dementia. Aside from cancer, we had to
rely on self-reports of chronic conditions. However, data comparing comorbidities self-
reported on the same survey we used (MHOS) versus abstraction of medical records suggest
reasonably good correspondence, with median specificity (% of time condition is not self-
reported when it is not in the medical record) and sensitivity (% of time condition is self-
reported when it is in the medical record) of 69 and 91 %, respectively [20]. In addition, the
data were collected using both mail surveys and telephone interviews and included some
proxy responses. But we adjusted for these variables in the regression model. Moreover, the
SEER-MHOS dataset includes four MHOS cohorts and data collected back in 1998.
However, average SF-6D scores for the four cohorts were exactly the same, indicating no
temporal shifts. While some preference-based measures (e.g., the EQ-5D) have been
criticized for lack of sensitivity [21], the results of this study suggest that the SF-6D is
sensitive to the impact of cancer on HRQOL. However, previous research indicates that
different preference measures may not yield the same results [22]. The current work needs to
be replicated in other large-scale surveys of cancer patients using different preference-based
measures.
This study provides important information about the relative burden of different chronic
conditions on HRQOL in Medicare beneficiaries. It indicates that a large number of
conditions are associated uniquely with decrements in health utility and that the cumulative
effects are substantial. In addition, distant stage of disease for the four big cancers (female
breast, prostate, colorectal, lung) is associated with large, negative impact on utility among
older individuals in the United States. The findings reported here are particularly important
given the aging US population and increasing number of persons 65 years and older. As
SEER-MHOS adds new cohorts and larger sample sizes by stage of disease become
available, further investigation of the impact of cancer and stage of disease will be possible.
Tracking the association of chronic conditions and stage of disease on HRQOL periodically
can give providers and federal agencies such as the Center for Medicare and Medicaid
Services important information about the extent to which the health needs of older
Americans are being addressed.
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Mean age (range) 74 (65–106) 74 (65–106) 75 (65–101)
Mean number of conditions over than cancer (range) 2.44 (0–13) 2.42 (0–13) 2.51 (0–13)
Male (%) 45 43 53
Race/ethnicity
 Hispanic (%) 7 8 5
 Non-hispanic white (%) 79 79 82
 Non-hispanic black (%) 5 5 5
 Asian (%) 5 5 4
 American Indian (%) 1 1 1
 Other race (%) 2 2 2
 Missing race (%) 1 1 1
 Married (%) 60 60 62
Education
 8th grade or less (%) 11 11 10
 Some high school (%) 14 14 14
High school graduate (%) 33 33 32
Some college (%) 24 24 25
4-year college graduate (%) 8 8 9
More than 4-year degree (%) 9 9 10
Income
 < $10,000 (%) 11 11 10
 $10,000–19,999 (%) 22 22 22
 $20,000–29,999 (%) 18 18 18
 $30,000–39,999 (%) 12 12 12
 $40,000–49,999 (%) 7 7 8
 $50,000–79,999 (%) 8 8 8
 $80,000 or more (%) 4 4 5
 Do not know/missing (%) 18 18 17
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 Melanoma (n = 1,135) −0.002 0.003 −0.48 0.630 0.728 0.799
 Endometrial cancer (n = 902) −0.006 0.004 −1.54 0.124 0.724 0.795
 Colorectal cancer (n = 3,012) −0.006 0.002 −2.87 0.004 0.724 0.795
 Female breast cancer (n = 4,311) −0.006 0.002 −3.85 0.000 0.724 0.795
 Prostate cancer (n = 5,593) −0.008 0.002 −4.78 0.000 0.722 0.793
 Bladder cancer (n = 1,299) −0.008 0.003 −2.98 0.003 0.722 0.793
 Non-Hodgkin lymphoma (n = 668) −0.012 0.005 −2.60 0.010 0.718 0.789
 Kidney cancer (n = 488) −0.014 0.004 −3.22 0.001 0.716 0.787
 Other cancer (n = 3,540) −0.016 0.002 −7.43 0.000 0.714 0.785
 Non-small cell lung cancer (n = 1,792) −0.024 0.002 −9.81 0.000 0.706 0.777
Non-cancer chronic conditions
 Myocardial infarction/heart attack (n = 11,982) −0.006 0.001 −4.79 0.000 0.725 0.795
 Hypertension (n = 66, 968) −0.013 0.001 −18.77 0.000 0.724 0.788
 Other heart disease (n = 25,455) −0.017 0.001 −21.18 0.000 0.716 0.794
 Angina/coronary artery disease (n = 18,017) −0.017 0.001 −18.93 0.000 0.715 0.784
 Diabetes (n = 20,089) −0.022 0.001 −23.22 0.000 0.712 0.779
 Arthritis of the hand (n = 40,402) −0.023 0.001 −25.71 0.000 0.714 0.778
 Congestive heart failure (n = 7,893) −0.029 0.001 −20.87 0.000 0.703 0.772
 Inflammatory bowel disease (n = 5,882) −0.031 0.001 −24.11 0.000 0.700 0.770
 Sciatica (n = 26,878) −0.037 0.001 −52.64 0.000 0.701 0.764
 Stroke (n = 9,479) −0.039 0.001 −30.42 0.000 0.694 0.762
 Chronic obstructive pulmonary disease/asthma (n =
5,445) −0.040 0.001 − 43.77 0.000 0.695 0.761
 Arthritis of the hip (n = 44,524) −0.044 0.001 −64.29 0.000 0.702 0.758
 Depressive symptoms (n = 14,815) −0.131 0.001 −131.29 0.000 0.614 0.670
The model adjusted for each chronic condition, education, age, and marital status, mode of data collection, race, and income. The regression model
had 43 degrees of freedom in the numerator and accounted for 39 % of the adjusted variance. The unstandardized beta coefficients column
indicates the direction and magnitude of difference in the adjusted SF-6D score for each chronic condition
*
Adjusted score is from recycled predictions with other independent variables fixed at their means. The adjusted score for those without a
condition was 0.749
**
Adjusted score is from recycled predictions with the other 22 conditions fixed at zero and other independent variables fixed at their means. The
adjusted score for those without a condition was 0.806
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